BridgeBio Oncology Therapeutics, Inc. - 10-Q Filing

BridgeBio Oncology Therapeutics filed a Form 10-Q for the quarter ended March 31, 2026. The filing includes financial data related to cash equivalents and marketable securities, including money market funds, commercial paper, corporate debt securities, certificates of deposit, and treasury bills. It also details equity components such as common stock, preferred stock, additional paid-in capital, and restricted stock units.

SEC EDGAR · May 12, 2026, 21:13 UTC

Tickers: $BBOT

Read the full article at SEC EDGAR

More Regulatory news

AUDIOEYE INC - 10-Q Filing SEC EDGAR · October 26, 2026, 21:11 UTC
ROCKWELL AUTOMATION, INC - 10-K Filing SEC EDGAR · November 12, 2026, 16:35 UTC
United KSK Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 16:29 UTC
AMERICAN SHARED HOSPITAL SERVICES - 8-K Filing SEC EDGAR · November 12, 2026, 16:27 UTC
VIVIC CORP. - 10-K Filing SEC EDGAR · November 12, 2026, 16:26 UTC
WOLVERINE WORLD WIDE INC /DE/ - 10-Q Filing SEC EDGAR · November 12, 2026, 16:24 UTC
BlueOne Technologies, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 16:20 UTC
Newton Golf Company, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 16:14 UTC
XBiotech Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:53 UTC
Cohen & Co Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:48 UTC